Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.
Future Market Insights2d
Global Oral Controlled Release Drug Delivery Technology Market Set to Reach USD 68.4 Billion by 2032
Oral Controlled Release Drug Delivery Technology Market is anticipated to reach a valuation of about USD 68.4 billion by 2032 ...
Renal & Urology News2d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
BioSpace3d
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
FiercePharma4d
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
TMCnet4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...